Use of ruxolitinib to control graft-versus-host-like disease in Omenn syndrome and successfully bridging to HSCT

Affiliations

¹ Department of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
² Hospital Pharmacy Unit, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
³ Department of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy; Department of Maternal, Infantile, and Urological Sciences, Sapienza, University of Rome, Rome, Italy.
⁴ Department of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy. Electronic address: pietro.merli@opbg.net.

Antonio Giacomo Grasso et al. J Allergy Clin Immunol Pract. 2021 Jun.

. 2021 Jun;9(6):2531-2533.e1.

doi: 10.1016/j.jaip.2021.02.019. Epub 2021 Feb 23.

¹ Department of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
² Hospital Pharmacy Unit, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
³ Department of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy; Department of Maternal, Infantile, and Urological Sciences, Sapienza, University of Rome, Rome, Italy.
⁴ Department of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy. Electronic address: pietro.merli@opbg.net.

No abstract available

Publication types